[go: up one dir, main page]

WO2008061673A3 - Drug discovery for cancer - Google Patents

Drug discovery for cancer Download PDF

Info

Publication number
WO2008061673A3
WO2008061673A3 PCT/EP2007/009910 EP2007009910W WO2008061673A3 WO 2008061673 A3 WO2008061673 A3 WO 2008061673A3 EP 2007009910 W EP2007009910 W EP 2007009910W WO 2008061673 A3 WO2008061673 A3 WO 2008061673A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
gamma
cancer
secretase
collection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2007/009910
Other languages
French (fr)
Other versions
WO2008061673A2 (en
Inventor
Loo Karen Miriam Johanna Van
Gerardus Johannes Maria Martens
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthon BV
Original Assignee
Synthon BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthon BV filed Critical Synthon BV
Publication of WO2008061673A2 publication Critical patent/WO2008061673A2/en
Publication of WO2008061673A3 publication Critical patent/WO2008061673A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to a method for identifying compounds which alter the activity of gamma- secretase, comprising providing a collection of compounds; contacting the compounds of the collection with a cell line or organism expressing gamma-secretase; measuring the gamma-secretase activity in the cell line or organism before and after the contact with the compound; and identifying the compounds in the collection that modulate the gamma-secretase activity of the cell line or organism as leads for the development of compounds for use in the treatment of cancer. The invention further relates to the compound thus identified and the use thereof in therapy.
PCT/EP2007/009910 2006-11-24 2007-11-08 Drug discovery for cancer Ceased WO2008061673A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EPPCT/EP2006/011266 2006-11-24
EP2006011266 2006-11-24

Publications (2)

Publication Number Publication Date
WO2008061673A2 WO2008061673A2 (en) 2008-05-29
WO2008061673A3 true WO2008061673A3 (en) 2008-10-02

Family

ID=39272707

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2007/009910 Ceased WO2008061673A2 (en) 2006-11-24 2007-11-08 Drug discovery for cancer

Country Status (1)

Country Link
WO (1) WO2008061673A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073630A2 (en) * 2003-02-18 2004-09-02 Roskamp Research Llc Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors
WO2004104037A1 (en) * 2003-05-26 2004-12-02 Sanofi-Aventis Deutschland Gmbh Method for screening inhibitors of the gamma-secretase
EP1702626A1 (en) * 2003-12-30 2006-09-20 Kowa Company Ltd. Inhibitor for the formation of gammad-secretase complex
WO2007028655A2 (en) * 2005-09-09 2007-03-15 H. Lundbeck A/S Drug discovery for neurodevelopmental disorders and their complications

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004073630A2 (en) * 2003-02-18 2004-09-02 Roskamp Research Llc Anti-angiogenic and anti-tumoral properties of beta and gamma secretase inhibitors
WO2004104037A1 (en) * 2003-05-26 2004-12-02 Sanofi-Aventis Deutschland Gmbh Method for screening inhibitors of the gamma-secretase
EP1702626A1 (en) * 2003-12-30 2006-09-20 Kowa Company Ltd. Inhibitor for the formation of gammad-secretase complex
WO2007028655A2 (en) * 2005-09-09 2007-03-15 H. Lundbeck A/S Drug discovery for neurodevelopmental disorders and their complications

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHIROTANI KEIRO ET AL: "Identification of distinct gamma-secretase complexes with different APH-1 variants", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 279, no. 40, 1 October 2004 (2004-10-01), pages 41340 - 41345, XP002418773, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2008061673A2 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
MX349787B (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor.
WO2010017515A3 (en) Breast cancer specific markers and methods of use
WO2008021183A3 (en) For the identification, assessment, and treatment of patients with cancer therapy
EA201100452A1 (en) TREATMENT OF INFLAMMATORY CONDITIONS
WO2010008739A3 (en) Aryl gpr119 agonists and uses thereof
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
WO2010091049A3 (en) Diagnosis and treatment of cancer
UY32177A (en) TREATMENT OF DIABETES IN PATIENTS WITH INSUFFICIENT GLUCEMIC CONTROL TO WEIGHT THERAPY WITH DRUG, ORAL OR NOT, ANTIDIABÉTICO
AU2011328009A8 (en) Compounds and methods for treating pain
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
WO2013009655A3 (en) Uses of labeled hsp90 inhibitors
WO2007123722A3 (en) Methods for prediction and prognosis of cancer, and monitoring cancer therapy
WO2008063842A3 (en) Methods of treating neuropathic pain with agonists of ppar-gamma
WO2006053043A3 (en) Methods of treating diabetes mellitus
WO2012078623A3 (en) Biomarkers for monitoring treatment of neuropsychiatric diseases
MY158428A (en) Topical composition for the treatment of actinic keratosis
WO2008127388A3 (en) Use of quantum system identification and quantum control techniques for medical diagnostic and therapeutic purposes
WO2006009765A3 (en) Methods for the identification and use of compounds suitable for the treatment of drug resistant cancer cells
WO2008013966A3 (en) Use of 8-quinolinol and its analogs to target cancer stem cells
MX2009008727A (en) Patch for cutaneous application.
GB201021794D0 (en) Treatment and diagnosis of behavioural disorders
WO2008118390A3 (en) Biomarkers for diagnostic and therapeutic methods
WO2009022988A3 (en) Vhz for diagnosis and treatment of cancer
IL207722A (en) Pyridopyrazinone derivatives as insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
EA201101300A1 (en) METHOD OR SYSTEM BASED ON BIOMARKERS INTENDED FOR MONITORING TREATMENT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07846619

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07846619

Country of ref document: EP

Kind code of ref document: A2